Press Release


February 9, 2017 – Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the Association of Academic Physiatrists
January 18, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Poster Presentations at ASCO 2017 Gastrointestinal Cancers Symposium
January 9, 2017 – Paris, France,
 
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
October 26, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society
October 19, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the Annual Meeting of the American Academy of Physical Medicine & Rehabilitation
September 30, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium
September 21, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine
September 15, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Eight Presentations for Dysport® (abobotulinumtoxinA) at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine
August 1, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older
June 4, 2016 - Basking Ridge, NJ (USA),
 
Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome
June 2, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Announces Data Presentations of Somatuline® Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
April 6, 2016 - Basking Ridge, NJ (USA),
 
Carcinoid Cancer Foundation and Self Care Catalysts Inc. to Provide a Free Digital Patient Support Application for Carcinoid and Neuroendocrine Tumor (NET) Patients, Sponsored in Part by Ipsen Biopharmaceuticals, Inc.
October 22, 2015 - Basking Ridge, NJ (USA),
 
Presentation of Results at the AACPDM Annual Meeting from a Phase III Trial Evaluating an Investigational Use of AbobotulinumtoxinA (Dysport®) in Children with Spastic Equinus Foot Deformity due to Cerebral Palsy
October 15, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Announces Eight Studies of Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society (NANETS) Symposium
October 1, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Announces Release of Additional Batch of Increlex® (mecasermin [rDNA origin] injection) in the U.S.
August 31, 2015 - Basking Ridge, NJ (USA),
 
Ipsen announces The Lancet Neurology publishes Dysport® Phase III registration trial results in adult patients with upper limb spasticity (ULS)
August 4, 2015 - Sacramento, CA (USA),
 
Ipsen Biopharmaceuticals, Inc. Receives Statewide Award for Achievements in Product Stewardship
July 16, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States
May 14, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Announces Data Presentations for Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
January 13, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals To Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium
December 16, 2014 - Basking Ridge, NJ (USA),
 
Ipsen announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the treatment of gastroenteropancreatic neuroendocrine tumors

December 1, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients

November 24, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARESTM, An Enhanced Patient Support Program

November 14, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Presents Dysport® (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly

November 6, 2014 - Basking Ridge, NJ (USA),

Ipsen Announces FDA Approval of a New Delivery Device for Somatuline® Depot® (lanreotide) Injection

November 5, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology

September 18, 2014 - Basking Ridge, NJ (USA),

Baseline Data from a Phase III Trial in Pediatric Cerebral Palsy Presented at Meeting of the American Academy for Cerebral Palsy and Developmental Medicine

September 10, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces Key Medical and Commercial Hires

September 1, 2014 - Basking Ridge, NJ (USA),

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review

August 26, 2014 - Basking Ridge, NJ (USA),

Ipsen Announces Second Resupply of Increlex®(mecasermin [rDNA origin] Injection) in the U.S. in 2014

August 20, 2014 - Basking Ridge, NJ (USA),

Ipsen Appoints Cynthia Schwalm as President and CEO of Ipsen North America

July 16, 2014 - Basking Ridge, NJ (USA),

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

July 1, 2014 - Basking Ridge, NJ (USA),

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

May 13, 2014 - Basking Ridge, NJ (USA),

Ipsen announces a step forward in the resupply of Increlex ® (mecasermin [rDNA origin] injection) in the U.S.

May 6, 2014 - Basking Ridge, NJ (USA),

Ipsen Announces Name Change for its Research and Development Affiliate in the U.S. From Biomeasure to Ipsen Bioscience, Inc.

17 January 2014 - Paris (France)

Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint

14 January 2014 - Paris (France)

Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors

26 September 2013 - Paris (France)

Ipsen to relocate US R&D activities to Cambridge, MA in 2014

15 July 2013 - Paris (France)

Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases